# 肽类API市场

> 肽类API市场研究报告按应用（制药、化妆品、营养保健品、诊断、研究）、按类型（治疗性肽、诊断性肽、化妆品肽）、按来源（天然、合成、重组）、按最终用途（医院、研究实验室、制药公司）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.86%
- **2024:** $ 119.06 Billion
- **2025:** $ 123.66 Billion
- **2035:** $ 180.59 Billion
- **Key Players:** Bachem AG (CH), Lonza Group AG (CH), Thermo Fisher Scientific Inc. (US), SYNlogic Inc. (US), PeptiDream Inc. (JP), Hapten Pharmaceuticals (US), CordenPharma (DE), Amgen Inc. (US), Merck KGaA (DE)

**Report ID:** MRFR/HC/38117-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/peptide-api-market-40143

---

## Market Summary

## **Peptide API Market Overview**

**As per MRFR analysis, the Peptide API Market Size was estimated at 34.65 (USD Billion) in 2022. The Peptide API Industry is expected to grow from 36.35 (USD Billion) in 2023 to 56.0 (USD Billion) by 2032. The Peptide API Market CAGR (growth rate) is expected to be around 4.92% during the forecast period (2024 - 2032).**

### **Key Peptide API Market Trends Highlighted**

The Peptide API Market is significantly influenced by several key drivers, including the increasing demand for peptide-based therapeutics and the growing prevalence of chronic diseases. The rise in research activities focused on peptide synthesis and formulation is also a major factor propelling market growth.

Additionally, advancements in technology, along with supportive government regulations, are further enhancing the landscape for peptide APIs. The pharmaceutical and biotechnology sectors are actively exploring these areas to develop targeted therapies that offer improved efficacy and safety profiles compared to traditional small molecules. The opportunities in the peptide API market are numerous, particularly with the continuing move towards customized medicine. Currently, companies are concentrating on creating novel peptide designs for a specific population, which enables targeted drug delivery systems to be developed.

In addition, the growth of health facilities and the increase of research and investments in developing countries serve opportunities for market participants. Collaborative efforts and partnerships between biotechnology companies and research centers are likely to advance the therapeutic progress of peptide drugs so as to fill market gaps and enhance patient care. Recent tendencies indicate a rising demand for biologics where peptides are seen as better and safer than traditional pharmaceuticals.

The emphasis on early-stage research and clinical trials has intensified, leading to a surge in the development of various peptide-based products. Digital technologies and automation are also being embraced to streamline peptide synthesis and production processes, resulting in lower costs and higher efficiency. As market dynamics evolve, the increasing integration of artificial intelligence and machine learning in peptide development offers exciting prospects for the future. Overall, the market is poised for continuous evolution, driven by these compelling trends and emerging opportunities.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Peptide API Market Drivers**

### **Increasing Demand for Targeted Therapies**

The growing focus on personalized medicine and targeted therapies is significantly driving the Peptide API Market Industry. As healthcare evolves, there is a noticeable shift from traditional treatment methods towards more individualized approaches that cater to the specific needs of patients. Peptides play a crucial role in this transition due to their ability to yield high specificity and potency in therapeutic applications. This shift is largely fueled by the rising incidence of chronic diseases and the need for innovative treatments that provide better efficacy while minimizing side effects.

Furthermore, advancements in peptide synthesis and delivery methods have enhanced the feasibility of developing new peptide-based drugs, thereby expanding the pipeline for pharmaceutical companies. The global healthcare landscape is evolving, with a portion highly focused on biological drugs, and peptides are among the most promising classes of biologics. In addition, the growing recognition of peptides as essential components in biotechnology and pharmaceutical developments is facilitating collaborations between industry players, academic institutions, and research organizations.

This collaborative environment is sparking innovation and leading to a richer variety of peptide API offerings that cater to niche medical conditions. Consequently, the rising inclination towards sustainable and cost-effective drug development platforms has positioned peptide-based APIs as attractive solutions for drug manufacturers aiming to meet market demands while reducing research and production costs. Overall, the expansive potential of peptides as powerful therapeutic agents is propelling significant investments in the field, further igniting the growth of the Peptide API Market Industry.

### **Technological Advancements in Peptide Synthesis**

Advancements in peptide synthesis technologies are also significantly driving the Peptide API Market Industry. Modern techniques such as solid-phase peptide synthesis (SPPS), microwave-assisted synthesis, and automated synthesizers have transformed how peptides are produced. These innovations not only enhance the efficiency and yield of peptide production but also allow for more complex and diverse peptide structures that can be tailored to specific therapeutic requirements.

Furthermore, automation in the synthesis process reduces human error, ensuring consistent quality and bolstering the overall reliability of peptide APIs. As a result, pharmaceutical companies are able to bring more peptide-based drugs to the market rapidly, responding to the increasing demand each has witnessed in recent years.

### **Rising Investments in Biopharmaceutical Research**

The increase in funding for biopharmaceutical research is another crucial driver propelling the Peptide [API Market](../../../reports/active-pharmaceutical-ingredients-market-1385) Industry. Governments and private investors are recognizing the potential of peptide therapeutics and are channeling more resources into research and development.

This trend is leading to the discovery of innovative peptide APIs that could address unmet medical needs across various therapeutic areas. Collaboration between biopharmaceutical companies and research institutions is fostering a conducive environment for innovation and accelerating the translation of research breakthroughs into tangible therapies, further fueling market growth.

## **Peptide API Market Segment Insights**

### **Peptide API Market Application Insights**

The Peptide API Market is a dynamic and rapidly evolving sector with a substantial application landscape encompassing various industries. In 2023, the overall market is valued at 36.35 USD Billion, with expected growth driven by increasing demand across several applications. Among these applications, the Pharmaceuticals segment holds a major share with a valuation of 15.0 USD Billion in 2023 and is poised for notable growth, reaching 24.0 USD Billion by 2032, indicating its significance in drug development and therapeutic usage.

This is primarily due to the rise in chronic diseases and the need for innovative treatment options, which underscore the critical role of peptide-based drugs in improving patient outcomes.

The Cosmetics segment follows closely, with a valuation of 7.5 USD Billion in 2023, projected to rise to 10.0 USD Billion by 2032. The growing consumer awareness regarding the benefits of peptide formulations in skincare products highlights its importance and the trend toward incorporating natural ingredients into cosmetics. Nutraceuticals is another important application, valued at 8.0 USD Billion in 2023, and is expected to grow to 12.0 USD Billion by 2032, reflecting the increasing focus on preventive healthcare and wellness. This shift towards health supplements contributes to the rising interest in peptide-rich nutritional products that promote overall well-being.

Diagnostics is valued at 3.0 USD Billion in 2023 and anticipated to reach 5.0 USD Billion by 2032, signifying the growing reliance on peptide-based biomarkers for disease detection and monitoring. Lastly, the Research application is valued at 2.85 USD Billion in 2023, projected to increase to 5.0 USD Billion by 2032, highlighting the continued investment in peptide research for various biomedical applications.

The Peptide API Market segmentation reflects a landscape that is not only expansive but also integral to key growth drivers like innovation in therapeutic development, the rising demand for cosmetic products with functional ingredients, and increased awareness of health and wellness trends.

The market growth is further supported by significant advancements in synthesis techniques, optimizing peptide stability and bioavailability, thus creating opportunities for enhanced product applications across all sectors. As the demand for peptide APIs intensifies, challenges such as regulatory hurdles and production costs will also need to be navigated, yet the opportunities presented by a focused approach to development and application continue to drive this dynamic market forward.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Peptide API Market Type Insights**

The Peptide [API Market](../../../reports/active-pharmaceutical-ingredients-market-1385) is poised for significant growth, with a valuation of 36.35 billion USD in 2023, increasing steadily over the years. The market comprises several types, broadly categorized into Therapeutic Peptides, Diagnostic Peptides, and Cosmetic Peptides, each playing a crucial role in the overall dynamics of the industry. Therapeutic Peptides have garnered substantial attention due to their applications in treating various diseases, thus providing numerous opportunities for pharmaceutical advancements. Diagnostic Peptides, pivotal in the development of accurate detection methods, contribute significantly to the healthcare sector by facilitating early disease diagnosis.

Meanwhile, Cosmetic Peptides have established their importance in beauty and skincare, driving market growth through the demand for anti-aging and rejuvenating products. The diverse applications of these types highlight their distinct roles within the Peptide API Market, reflecting the industry's adaptability to evolving consumer needs. As this market progresses, ongoing innovations and trends such as personalized medicine are expected to further enhance the relevance of these segments in the approaching years. A combination of technological advancements and a growing aging population may serve as primary growth drivers.

### **Peptide API Market Source Insights**

The Peptide API Market, valued at 36.35 USD Billion in 2023, showcases diverse market dynamics influenced by its Source segmentation. The natural source holds a significant position within the market, owing to its widespread application in drug development, highlighting the growing focus on biologically derived peptides. Synthetic peptides also play a crucial role in catering to the rising demand for customization and scalability in production, tapping into advanced technologies to enhance synthesis processes. Meanwhile, recombinant peptides have gained traction due to their high specificity and increased production efficiencies, making them essential in therapeutic applications.

The interplay between these sources contributes to the rapidly evolving landscape of the Peptide API Market, with market growth driven by advancements in research and the rising prevalence of chronic diseases. Other factors, such as an increase in healthcare expenditure and evolving healthcare policies, further fuel demand across the board. However, the market does face challenges, including stringent regulatory frameworks and high production costs that may limit growth potential. Nevertheless, the Peptide API Market continues to expand, with numerous opportunities for innovation and development in various applications.

### **Peptide API Market End Use Insights**

In 2023, the Peptide API Market was valued at approximately 36.35 USD Billion, driven by the diverse applications across various end-use sectors. Among these, hospitals play a crucial role, as they increasingly rely on peptide APIs for advanced therapeutic applications and personalized medicine, thereby supporting the demand within the healthcare industry.

Research laboratories constitute another significant area, as they utilize peptide APIs for drug discovery and development, paving the way for innovative therapeutic solutions. Pharmaceutical companies dominate the market, capitalizing on the growing number of peptide-based drugs entering the pipeline, which reflects a shift toward targeted therapies.

The Peptide API Market revenue is influenced by factors such as rising healthcare expenditure, increasing prevalence of chronic diseases, and advancements in peptide synthesis technologies. However, challenges like regulatory hurdles and high production costs may impact growth.

Despite this, opportunities for expansion remain strong, particularly in developing markets and through enhanced research collaborations, which are essential for the evolution of the peptide API landscape. Furthermore, continuous innovation within the Peptide API Market industry enhances its potential, attracting investments and driving overall market growth.

### **Peptide API Market Regional Insights**

The Peptide API Market has exhibited strong regional performance, with North America holding a majority, valued at 14.5 USD Billion in 2023 and expected to grow to 22.0 USD Billion by 2032. This region benefits from advanced healthcare infrastructure and significant investment in pharmaceutical research, making it a dominant player.

Europe follows, holding a valuation of 10.5 USD Billion in 2023 and projected to reach 16.5 USD Billion, supported by robust regulatory frameworks and an increasing demand for biosimilars. The APAC region, valued at 7.5 USD Billion, is also on an upward trajectory to 12.5 USD Billion, driven by rising healthcare expenditures and a growing population.

South America, while smaller with a valuation of 2.0 USD Billion, is expected to grow to 3.0 USD Billion, indicating emerging opportunities within the market. Conversely, the MEA region is currently valued at 2.85 USD Billion but is projected to decline to 2.0 USD Billion, suggesting challenges in market penetration and healthcare access.

Overall, the Peptide API Market shows varying degrees of growth across its regional segmentation, highlighting the diverse opportunities and challenges within the industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Peptide API Market Key Players and Competitive Insights**

The Peptide API Market has experienced significant growth and transformation in recent years, driven by increasing demand for peptide-based therapeutics and their applications in various therapeutic areas such as oncology, diabetes, and metabolic disorders. The competitive landscape of this market is characterized by a diverse range of players, including major pharmaceutical companies, biotechnology firms, and contract manufacturing organizations.

These competitors are focused on innovation, scaling their production capabilities, and striving to optimize the efficiency and purity of peptide synthesis. The strategic collaborations, investments in research and development, and acquisition activities among companies are pivotal in enhancing their market positions and technological advancements. This market offers ample opportunities due to its expanding applications, which has encouraged investments aimed at improving the therapeutic efficacy and safety profiles of peptide-based drugs.

PeptiDream stands out in the Peptide API Market due to its unique discovery platform that leverages a proprietary peptide-drug conjugate technology. The company has developed a strong reputation for its ability to create high-value peptide therapeutics efficiently. With a commitment to innovation, PeptiDream has established collaborations with various pharmaceutical companies, accelerating the development of novel therapeutics.

The strengths of PeptiDream lie in its extensive library of peptides, which allows for diverse applications in drug development, leading to the creation of differentiated products that cater to unmet medical needs. The cutting-edge technology utilized by PeptiDream not only enhances the production of peptide APIs but also ensures the therapeutic candidates developed are of superior quality and optimized for efficacy, addressing the distinct demands of the evolving healthcare landscape.

Polypeptide Group has firmly established itself as a prominent player within the Peptide API Market, renowned for its comprehensive suite of services that include the development and manufacturing of a wide range of peptide APIs. The company boasts a robust manufacturing footprint, which encompasses state-of-the-art facilities, allowing for scalable production tailored to clients' specific requirements.

Polypeptide Group shows exceptional strength in its expertise in peptide synthesis, which is coupled with the seamless integration of enabling technologies that enhance efficiency and yield. Their commitment to quality assurance and regulatory compliance further elevates their position in the market, making them a trusted partner for clients looking to develop peptide-based therapeutics.

The firm continues to invest in cutting-edge technologies and innovative strategies to meet the increasing demand for complex peptides, reflecting its proactive approach to addressing the evolving dynamics of the peptide API market.

### **Key Companies in the Peptide API Market Include**

- PeptiDream
- Polypeptide Group
- Corden Pharma
- Aji BioPharma
- **[Lonza](https://www.lonza.com/advanced-synthesis/small-molecules/drug-substance)**
- Ipsen
- Wuxi AppTec
- Bachem
- Covalent Bioscience
- Amgen
- Hochst GmbH
- Merck KGaA
- Novo Nordisk
- Synthetech
- Ferring Pharmaceuticals

## Peptide Api Market Industry Developments

- **Q2 2024: Bachem opens new large-scale peptide and oligonucleotide production facility in Switzerland** Bachem announced the opening of a new large-scale manufacturing facility in Bubendorf, Switzerland, to expand its capacity for peptide and oligonucleotide active pharmaceutical ingredients (APIs), supporting increased demand from pharmaceutical partners.
- **Q1 2024: CordenPharma Announces Expansion of Peptide API Manufacturing Capacity in Colorado** CordenPharma announced the completion of a major expansion at its Colorado facility, increasing its peptide API production capabilities to meet growing demand from global pharmaceutical clients.
- **Q2 2024: PolyPeptide Group and Zealand Pharma enter into long-term peptide API manufacturing agreement** PolyPeptide Group signed a long-term agreement with Zealand Pharma to manufacture peptide APIs for Zealand's pipeline of peptide-based therapeutics.
- **Q1 2024: Lonza Expands Peptide Manufacturing Capabilities with New Suite in Visp, Switzerland** Lonza announced the opening of a new manufacturing suite dedicated to peptide API production at its Visp site, enhancing its capacity to support clinical and commercial supply.
- **Q2 2024: Bachem and Novo Nordisk extend peptide API supply agreement** Bachem and Novo Nordisk extended their existing supply agreement for the manufacture of peptide APIs used in Novo Nordisk's diabetes and obesity drug portfolio.
- **Q1 2025: AmbioPharm Announces Opening of New Peptide API Manufacturing Facility in South Carolina** AmbioPharm opened a new manufacturing facility in North Augusta, South Carolina, to increase its peptide API production capacity and support growing demand from pharmaceutical partners.
- **Q2 2024: CordenPharma and PepThera Announce Strategic Partnership for Peptide API Development** CordenPharma and PepThera entered a strategic partnership to co-develop and manufacture peptide APIs for PepThera's clinical pipeline.
- **Q1 2025: Bachem signs multi-year peptide API supply contract with major US biotech** Bachem signed a multi-year contract to supply peptide APIs to a leading US biotechnology company for use in late-stage clinical development and commercial products.
- **Q2 2024: PolyPeptide Group appoints new Chief Executive Officer** PolyPeptide Group announced the appointment of a new CEO to lead the company through its next phase of growth in the peptide API sector.
- **Q1 2024: Lonza and PeptiDream Announce Collaboration to Develop and Manufacture Peptide APIs** Lonza and PeptiDream entered into a collaboration agreement to develop and manufacture peptide APIs for PeptiDream's therapeutic candidates.
- **Q2 2025: AmbioPharm secures multi-million dollar contract to supply peptide APIs to European pharma company** AmbioPharm announced it has secured a multi-million dollar contract to supply peptide APIs to a major European pharmaceutical company for use in commercial drug products.
- **Q1 2025: Bachem raises CHF 200 million in equity to fund peptide API capacity expansion** Bachem completed a CHF 200 million equity raise to finance the expansion of its peptide API manufacturing capacity in response to increased global demand.

## **Peptide API Market Segmentation Insights**

### **Peptide API Market Application Outlook**

- Pharmaceuticals
- Cosmetics
- Nutraceuticals
- Diagnostics
- Research

### **Peptide API Market Type Outlook**

- Therapeutic Peptides
- Diagnostic Peptides
- Cosmetic Peptides

### **Peptide API Market Source Outlook**

- Natural
- Synthetic
- Recombinant

### **Peptide API Market End Use Outlook**

- Hospitals
- Research Laboratories
- Pharmaceutical Companies

### **Peptide API Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### 肽开发的监管支持

监管机构越来越认识到肽的治疗潜力，这促进了肽活性药物成分市场的增长。最近旨在简化肽类药物审批流程的举措鼓励制药公司投资于肽研究。例如，创新疗法的快速审查通道的引入正在促进肽活性药物成分更快地进入市场。这种监管支持至关重要，因为它不仅减少了药物开发的时间和成本，还增强了肽类解决方案在治疗各种医疗条件方面的吸引力。因此，肽活性药物成分市场预计将经历加速增长，受益于有利的监管环境。

### 慢性疾病的日益普遍

慢性疾病（如糖尿病、癌症和心血管疾病）发病率的上升是肽API市场的主要驱动力。随着医疗系统努力应对这些疾病，对创新治疗解决方案（包括基于肽的药物）的需求正在上升。根据最新数据，肽治疗市场预计到2026年将达到约500亿美元，反映出约8%的复合年增长率。这一增长表明对肽API在有效治疗选择中的日益依赖。因此，制药公司正在大力投资于研发，以创造新型肽治疗药物，从而推动肽API市场的发展。

### 肽合成中的技术进步

肽合成中的技术创新正在改变肽API市场。自动合成器和先进的纯化技术的出现提高了肽生产的效率和可扩展性。这些进展使制造商能够以更低的成本生产高质量的肽，从而使其在治疗应用中更具可及性。此外，人工智能在药物发现过程中的整合正在简化潜在肽候选者的识别。因此，市场正在见证肽基药物开发的激增，这些药物因其特异性和减少的副作用而越来越受到青睐。这一趋势可能会持续下去，进一步巩固肽API在制药领域的地位。

### 对靶向疗法的需求上升

针对性疗法的日益偏好正在重塑肽活性药物市场。患者和医疗服务提供者越来越寻求提供精准和最小副作用的治疗选择。肽类药物因其能够选择性地靶向特定受体或通路而在这种情况下获得了关注。针对性疗法的市场预计将显著增长，估计到2027年可能达到1000亿美元。这一趋势鼓励制药公司投资开发与个性化医疗需求相一致的肽活性药物。因此，肽活性药物市场可能会从这一向更有效和量身定制的治疗解决方案的转变中受益。

### 增加对生物制药研究的投资

生物制药研究的投资激增正在显著影响肽类活性药物成分市场。随着越来越多的生物制药公司专注于基于肽的疗法，市场正在经历强劲的增长。预计到2025年，生物制药研究资金将超过2000亿美元，其中相当一部分将用于肽的研究和开发。这一资金的涌入正在促进新型肽类活性药物成分的探索，这些成分正在被开发以更有效地针对特定疾病。因此，肽类活性药物成分市场有望扩张，推动这一市场的是持续的创新和新治疗肽的发现。

## Future Outlook

肽类API市场预计将在2024年至2035年间以3.86%的年均增长率增长，推动因素包括对治疗药物的需求增加和肽合成技术的进步。

**New opportunities:**

- 进入新兴市场，提供量身定制的肽解决方案。 开发利用肽活性药物成分的个性化医疗平台。 投资于自动化肽合成技术以提高成本效率。

到2035年，肽类API市场预计将实现强劲增长，成为制药行业的关键参与者。

## Segment Insights

### 按应用：制药（最大）与化妆品（增长最快）

肽类API市场展现出多样化的应用格局，制药行业占据最大份额。该应用主要集中在开发用于各种治疗的治疗性肽，包括癌症、糖尿病和激素疗法。在制药行业之后，营养保健品和诊断领域正在获得关注，反映出人们对健康和保健日益增长的兴趣，而研究应用对于肽类开发的未来创新至关重要。

制药（主导）与化妆品（新兴）

制药行业在肽API市场中占据主导地位，利用其广泛的研究基础和临床应用能力。治疗性肽因其特异性和与传统药物相比的副作用减少而获得了显著认可。相反，化妆品行业正迅速崛起，成为一个重要参与者，推动力来自对抗衰老产品和皮肤再生的需求。化妆品肽的配方旨在增强皮肤健康，促进胶原蛋白生成，并提供水分保持，助力该细分市场的快速增长。随着消费者对肽的益处认识的提高，该细分市场预计将占据更大的市场份额，并挑战制药行业的传统主导地位。

### 按类型：治疗性肽（最大）与美容肽（增长最快）

在肽类API市场中，各种类型的市场份额分布相当显著。治疗性肽由于其在药物配方中的广泛应用以及持续的研发投资，拥有最大的市场份额。诊断性肽虽然重要，但与治疗性肽相比，占据的份额较小。另一方面，美容肽正迅速获得关注，因为消费者越来越多地寻求富含肽的护肤产品，这增强了整体市场动态。

治疗性肽（主导）与美容肽（新兴）

治疗性肽目前是肽API市场的主导力量，因为它们在开发各种疾病的新疗法中发挥着关键作用。它们的广泛应用涵盖肿瘤学、内分泌学和心脏病学，受到科学进步和医疗支出增加的推动。相比之下，美容肽正在迅速崛起，吸引着越来越多关注抗衰老和皮肤再生的消费者群体。该细分市场的增长得益于创新配方和对肽在化妆品中益处的日益认识。这些趋势表明对两个细分市场的强劲投资，治疗性肽作为成熟的市场，而美容肽则代表了肽应用的不断演变。

### 按来源：自然（最大）与合成（增长最快）

肽类API市场分为三大主要来源：天然肽、合成肽和重组肽。在这三者中，天然肽占据最大的市场份额，受益于其在各种生物制药应用中的普遍性。然而，合成肽正在获得关注，预计在未来几年将显著增长。这一转变反映了对定制肽的日益增长的需求以及合成技术的进步，使得合成肽部分成为值得关注的领域。

天然（主导）与合成（新兴）

天然肽源自生物来源，因其在治疗中的有效性和接受度而在肽API市场中占据主导地位。这些肽被身体自然识别，从而导致较少的副作用和改善的患者结果。另一方面，合成肽正在成为一个重要的参与者。它们提供定制化解决方案，使得开发自然肽无法实现的新型治疗成为可能。这种适应性推动了创新，并将合成肽定位为未来研究和开发的关键领域。

### 按最终用途：医院（最大）与制药公司（增长最快）

肽类API市场展示了多样化的最终用途应用，其中医院占据了最大的份额。该细分市场在肽类治疗药物的管理中发挥着至关重要的作用，为需要复杂治疗的患者提供必要的服务。另一方面，制药公司正在迅速扩大其市场份额，推动这一增长的因素包括研发活动的增加和对新型肽类药物需求的激增。这一动态的市场环境促进了行业内的竞争和创新。

医院（主导）与研究实验室（新兴）

医院在肽API市场中仍然是主导的最终使用细分市场，主要是由于它们在治疗应用和病人护理中的关键作用。它们在各种治疗方案中使用大量的肽API，建立了稳定的需求。相比之下，研究实验室正在成为关键参与者，因为它们专注于创新的肽研究和开发。这些实验室对于探索新的治疗特性和增强肽合成技术至关重要。医院与研究机构之间的互动加强了基于肽的药物的管道，使它们成为肽治疗不断发展的格局中的重要贡献者。

## Regional Market Share Analysis

肽 API 市场在各地区表现强劲，北美占据主导地位，2023 年估值为 145 亿美元，预计到 2032 年将增长至 220 亿美元。该地区受益于先进的医疗基础设施和对制药研究的重大投资，使其成为主导参与者。

欧洲紧随其后，2023 年估值为 105 亿美元，预计将达到 165 亿美元，得益于强有力的监管框架和对生物仿制药日益增长的需求。亚太地区估值为 75 亿美元，也在向 125 亿美元的上升轨道上，受到医疗支出增加和人口增长的推动。

南美洲虽然规模较小，估值为 20 亿美元，但预计将增长至 30 亿美元，表明市场中出现了新兴机会。相反，中东和非洲地区目前估值为 28.5 亿美元，但预计将下降至 20 亿美元，这表明市场渗透和医疗获取方面存在挑战。

总体而言，肽 API 市场在其区域细分中显示出不同程度的增长，突显了行业内多样的机会和挑战。

来源：初步研究，二次研究，_市场研究未来_数据库和分析师评审

## Competitive Benchmarking

肽API市场近年来经历了显著的增长和转型，主要受到肽类治疗药物及其在肿瘤学、糖尿病和代谢疾病等多个治疗领域应用需求增加的推动。该市场的竞争格局由多样化的参与者构成，包括主要制药公司、生物技术公司和合同制造组织。

这些竞争者专注于创新，扩大生产能力，并努力优化肽合成的效率和纯度。公司之间的战略合作、研发投资和收购活动在提升其市场地位和技术进步方面至关重要。由于其不断扩展的应用，该市场提供了丰富的机会，鼓励投资以提高肽类药物的治疗效果和安全性。

PeptiDream在肽API市场中脱颖而出，得益于其独特的发现平台，利用专有的肽-药物偶联技术。该公司因其高效创造高价值肽类治疗药物的能力而建立了良好的声誉。PeptiDream致力于创新，与多家制药公司建立了合作关系，加速新型治疗药物的开发。

PeptiDream的优势在于其广泛的肽库，这使得其在药物开发中具有多样化的应用，能够创造出满足未满足医疗需求的差异化产品。PeptiDream所采用的尖端技术不仅提升了肽API的生产，还确保所开发的治疗候选药物具有优越的质量和优化的疗效，以满足不断变化的医疗保健环境的独特需求。

Polypeptide Group在肽API市场中稳固地确立了其作为重要参与者的地位，以其全面的服务套件而闻名，包括开发和制造多种肽API。该公司拥有强大的制造能力，涵盖了最先进的设施，能够根据客户的具体要求进行可扩展的生产。

Polypeptide Group在肽合成方面展现出卓越的实力，并与增强效率和产量的支持技术无缝集成。他们对质量保证和合规性的承诺进一步提升了他们在市场中的地位，使其成为希望开发肽类治疗药物的客户值得信赖的合作伙伴。

该公司继续投资于尖端技术和创新策略，以满足对复杂肽日益增长的需求，反映出其积极应对肽API市场不断变化动态的主动性。

## Recent News & Developments

- **2024年第二季度：Bachem在瑞士开设新的大规模肽和寡核苷酸生产设施** Bachem宣布在瑞士布本多夫开设一座新的大规模制造设施，以扩大其肽和寡核苷酸活性药物成分（API）的生产能力，以支持制药合作伙伴日益增长的需求。
- **2024年第一季度：CordenPharma宣布在科罗拉多州扩展肽API市场制造能力** CordenPharma宣布在其科罗拉多州设施完成了一项重大扩展，增加了其肽API生产能力，以满足全球制药客户日益增长的需求。
- **2024年第二季度：PolyPeptide Group与Zealand Pharma签署长期肽API制造协议** PolyPeptide Group与Zealand Pharma签署了一项长期协议，为Zealand的肽类治疗药物管线制造肽API。
- **2024年第一季度：Lonza在瑞士Visp扩展肽制造能力，开设新生产套件** Lonza宣布在其Visp工厂开设一套专门用于肽API生产的新制造套件，增强其支持临床和商业供应的能力。
- **2024年第二季度：Bachem与Novo Nordisk延长肽API供应协议** Bachem与Novo Nordisk延长了现有的肽API制造供应协议，用于Novo Nordisk的糖尿病和肥胖药物组合。
- **2025年第一季度：AmbioPharm在南卡罗来纳州开设新的肽API市场制造设施** AmbioPharm在南卡罗来纳州北奥古斯塔开设了一座新的制造设施，以增加其肽API生产能力，并支持制药合作伙伴日益增长的需求。
- **2024年第二季度：CordenPharma与PepThera宣布战略合作伙伴关系，开发肽API市场** CordenPharma与PepThera达成战略合作伙伴关系，共同开发和制造PepThera的临床管线所需的肽API。
- **2025年第一季度：Bachem与一家主要美国生物技术公司签署多年肽API供应合同** Bachem与一家领先的美国生物技术公司签署了一项多年合同，供应肽API，用于后期临床开发和商业产品。
- **2024年第二季度：PolyPeptide Group任命新首席执行官** PolyPeptide Group宣布任命新首席执行官，以引领公司在肽API领域的下一个增长阶段。
- **2024年第一季度：Lonza与PeptiDream宣布合作开发和制造肽API** Lonza与PeptiDream达成合作协议，共同开发和制造PeptiDream的治疗候选药物所需的肽API。
- **2025年第二季度：AmbioPharm获得数百万美元合同，向欧洲制药公司供应肽API** AmbioPharm宣布已获得一项数百万美元的合同，向一家主要的欧洲制药公司供应肽API，用于商业药品。
- **2025年第一季度：Bachem筹集2亿瑞士法郎股权资金，以资助肽API产能扩张** Bachem完成了2亿瑞士法郎的股权融资，以资助其肽API制造能力的扩张，以应对全球需求的增加。

## Report Scope

| 2024年市场规模 | 119.06（十亿美元） |
| --- | --- |
| 2025年市场规模 | 123.66（十亿美元） |
| 2035年市场规模 | 180.59（十亿美元） |
| 年复合增长率（CAGR） | 3.86%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 肽合成技术的进步提高了肽活性药物成分市场的生产效率。 |
| 主要市场动态 | 对肽类治疗药物的需求上升推动了肽活性药物成分市场的创新和竞争。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 到2035年，肽API市场的预计市场估值是多少？**
A: The Peptide API Market is projected to reach a valuation of 180.59 USD Billion by 2035.

**Q: What was the overall market valuation of the Peptide API Market in 2024?**
A: 在2024年，肽API市场的整体市场估值为1190.6亿美元。

**Q: What is the expected CAGR for the Peptide API Market during the forecast period 2025 - 2035?**
A: 在2025年至2035年的预测期内，肽API市场的预期CAGR为3.86%。

**Q: 到2035年，哪个应用领域预计将拥有最高的估值？**
A: 制药应用领域预计到2035年将达到700亿美元的估值。

**Q: 到2035年，化妆品肽细分市场的预计估值是多少？**
A: The Cosmetic Peptides segment is projected to reach a valuation of 60.59 USD Billion by 2035.

**Q: 哪个关键参与者以其在肽API市场的显著存在而闻名？**
A: Bachem AG 被认为是肽 API 市场的重要参与者，具有显著的市场份额。

**Q: What is the expected valuation for the Synthetic Peptides source by 2035?**
A: The Synthetic Peptides source is expected to reach a valuation of 75.0 USD Billion by 2035.

**Q: How does the valuation of Therapeutic Peptides compare to Diagnostic Peptides in 2035?**
A: 到2035年，治疗性肽的预计价值将达到700亿美元，超过诊断性肽，后者预计为500亿美元。

**Q: 到2035年，研究实验室最终用途细分市场的预期估值是多少？**
A: 研究实验室最终用途细分预计到2035年将达到350亿美元的估值。

**Q: Which company is a notable competitor in the Peptide API Market alongside Lonza Group AG?**
A: 赛默飞世尔科技公司是肽API市场上与隆泽集团AG并列的一个显著竞争者。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/peptide-api-market-40143*